Kelly McKee

“Yeah, so with the caveat that I'm not an oncologist, so I'm going to sort of stumble my way through this a little bit. So the major pathologic response has been defined for the 689 study, and it has to do with, obviously, the extent of response in the resected tumor tissue that's obtained during the trial.”

“Right now, we are projecting enrollment to begin around the 1st of October, the early part of October of 2025. That’s being driven by the sort of manufacturing timelines.”

“First of all, as far as the impact on the vaccine market overall, I think everybody sort of recognizes that the mRNA vaccine sales have been considerably lower than they were in the first stages of the pandemic, for sure.”

“That's really kind of a hard question to answer. We have proof-of-concept in a general sense from the Phase 1 study that's already been completed in that we demonstrated that injection of tumors with Gedeptin and followed by fludarabine infusions shrink the tumors.”